Lakewood-Amedex Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
LABT Nasdaq 2836 lakewoodamedex.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lakewood-Amedex Biotherapeutics, Inc.

LABT: Advancing Toward Phase 2a Study of Nu-3 in Infected Diabetic Foot Ulcers - Aug 26th, 2026 7:26 am
Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company - Aug 25th, 2026 3:36 pm
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria - Jul 22nd, 2026 6:02 am
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel - Jul 15th, 2026 6:02 am
CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics - Jul 13th, 2026 10:35 am
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance - Jul 7th, 2026 6:02 am
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - Jun 26th, 2026 6:35 am
Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers - Jun 25th, 2026 6:02 am
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th - Jun 23rd, 2026 6:35 am
LABT: Initiating Coverage of Lakewood-Amedex; Building a Next-Generation Antimicrobial Platform - Jun 23rd, 2026 3:20 am
Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections - Jun 22nd, 2026 6:02 am
Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum - Jun 16th, 2026 6:02 am
Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers - May 27th, 2026 6:02 am
Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers - May 18th, 2026 6:02 am
Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 - May 12th, 2026 6:02 am
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors - Apr 28th, 2026 5:33 am